Investor Update

Reminder: Invitation to Roche’s virtual event on 24-month data of Evrysdi in patients with type 2 or type 3 spinal muscular atrophy presented at the 2021 MDA virtual conference

We are pleased to invite investors and analysts to participate in our virtual event on Friday, 19 March, 2021, highlighting Roche data presented during the 2021 Muscular Dystrophy Association - MDA -Virtual Clinical and Scientific Conference, from 15th to 18th March.

14:00 – 15:00 CET / 13:00 - 14:00 GMT
9:00 – 10:00 am EDT / 6:00 – 7:00 am PDT

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 1pm CET on the day of the event. > click here


  • Phase II/III SUNFISH part 2: 24-month efficacy and safety of risdiplam in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophy
    Paulo Fontoura, M.D. Ph.D., Global Head Neuroscience and Rare Diseases Clinical Development
  • Roche Neuroscience and Rare Disease franchise update
    Simona Skerjanec, Therapeutic Area Head Neuroscience and Rare Diseases, Global Product Strategy
  • Q&A
    Karl Mahler, Head of Investor Relations and Roche Group Planning

Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to

A replay of the event will be available via >

*privacy notice

Best regards,

Karl Mahler
Head of Investor Relations and Roche Group Planning

Sabine Borngräber
Investor Relations Officer
Roche Investor Relations 
Dr. Karl Mahler
Phone: +41 61 68-78503

Jon Kaspar Bayard
Phone: +41 61 68-83894
Dr. Sabine Borngräber
Phone: +41 61 68-88027

Dr. Bruno Eschli
Phone: +41 61 68-75284
Dr. Birgit Masjost
Phone: +41 61 68-84814
Dr. Gerard Tobin
Phone: +41 61 68-72942
Investor Relations North America 
Loren Kalm
Phone: +1 650 225 3217
Dr. Lisa Tuomi
Phone: +1 650 467 8737